
1. gene ther. 2009 dec;16(12):1441-51. doi: 10.1038/gt.2009.103.

a modified e2f-1 promoter improves efficacy toxicity ratio oncolytic
adenoviruses.

rojas jj(1), cascallo m, guedan s, gros a, martinez-quintanilla j, hemminki a,
alemany r.

author information: 
(1)translational research laboratory, idibell-institut catal√† d'oncologia,
l'hospitalet de llobregat, barcelona, spain.

the e2f-1 promoter used confer tumor-selective e1a expression in
oncolytic adenoviruses. tumor specificity mainly conferred unique
structure e2f-responsive sites organized palindromes. binding the
e2f-prb complex palindromes results repression transcription in
normal cells. owing deregulation rb/p16 pathway tumor cells, binding
of free e2f activates transcription initiates autoactivation loop
involving e1a e4-6/7. icovir-7 new oncolytic adenovirus designed to
increase e2f dependency e1a gene expression. incorporates additional
palindromes e2f-responsive sites insulated e2f-1 promoter controlling
e1a-delta24. e2f palindromes inhibited replication normal cells, resulting
in low systemic toxicity high doses immunocompetent mice. delta24
deletion avoids loop e2f-mediated self-activation nontumor cells.
importantly, additional e2f-binding hairpins boost positive feedback loop
on basis e1a-mediated transcriptional regulation e4-6/7 turned in
cancer cells increased antitumoral potency shown murine subcutaneous
xenograft models treated intravenous injection. results suggest the
unique genetic combination featured icovir-7 may promising treating
disseminated neoplasias.

doi: 10.1038/gt.2009.103 
pmid: 19710704  [indexed medline]

